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Background:Primary ovarian and cervicalmelanomas are extremely rare tumorswith a poor prognosis. Diagnosis
requires a high index of suspicion as presentation can mimic benign conditions clinically and other neoplasms
histologically.
Cases: A 41 year-old with an adnexal mass underwent surgical staging for a stage IA ovarian melanoma. Imaging
revealed a brain metastasis treated with radiation. Subsequent nodal recurrence was treated with immune and
targeted therapies. She is alive with disease at 61 months follow-up. A 54 year-old presented after endocervical
melanoma was diagnosed with polypectomy. She underwent radical hysterectomy, lymphadenectomy, and ad-
juvant brachytherapy. Immediate post-treatment imaging revealed widespread liver and pulmonarymetastasis,
currently being treated with ipilimumab.
Conclusion: Immunohistochemistry can facilitate the diagnosis of gynecologic melanoma, and multidisciplinary
treatment is recommended.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rates of malignant melanoma have increased dramatically over the
last 20 years with 76,100 new diagnoses expected in 2014 (Siegel
et al., 2014). Of these, genital tractmelanomasmake up 0.23% of all mel-
anoma cases and 18% of mucosal melanomas (Sugiyama et al., 2008).
The majority of melanoma arising in the genital tract is vulvovaginal
in origin. Other gynecologic sites are extremely rarewith approximately
81 primary cervical melanoma cases and 42 primary ovarianmelanoma
cases reported in the literature, themajority of the latter are found in as-
sociation with ovarian teratomas (Sugiyama et al., 2008). Presentation
of these raremalignancies can be similar to benign neoplastic processes,
and pathologic assessment can be complicated by the heterogeneous
appearance of these tumors. Here, we report two rare cases of gyneco-
logic melanomas: primary ovarian melanoma, alive with disease at 62
months follow-up, and stage IB1 endocervical melanoma with rapid
disease progression.Cases
Case 1: A 41 year old presented with an abdominopelvic mass,
cystic with septations and measuring 16 × 17 × 12 cm on axial imag-
ing. Surgical evaluation was recommended and intraoperativec Oncology, Magee-Women's
, 300 Halket Street, Suite 2130
17.
. This is an open access article underfrozen section revealed a poorly-differentiated epithelial neoplasm.
Complete surgical staging was performed with hysterectomy, bilateral
salpingooophorectomy, pelvic and paraaortic lymphadenectomy,
omentectomy, and appendectomy. Her post-operative recovery was
uncomplicated. Final histopathology revealed a stage IA ovarian mela-
noma. Immunostains for S100, HMB-45, and Mart-1 were positive
(see Fig. 1). Interestingly, there was not an associated teratoma, and a
thorough skin survey failed to reveal another primary lesion.
Metastatic evaluation 2 months after diagnosis revealed a 1.2 cm
brain metastasis, but no other diseases. She underwent stereotactic ra-
diosurgery and adjuvant high-dose alpha 2B interferon. Seven months
after completion of primary therapy and 25 months after diagnosis,
she recurred in the paraaortic lymph nodes and had a partial response
with high-dose interleukin-2 and aﬂibercept, which was durable on
maintenance aﬂibercept. She underwent surgical resection for residual
paraaortic disease, and pathologic evaluation identiﬁed a BRAF muta-
tion. Subsequent therapy included the targeted agent vemurafenib,
which she progressed on after 8months of therapy, followed by a partial
response to ipilimumab, which was durable for 14 months. She is
currently on pembrozlizumab 69 months after diagnosis.
Case 2: A 54 year old post-menopausal female was referred following
the removal of a 4 cm endocervical polypwith ﬁnal histopathology dem-
onstrating a malignant melanoma with positive margins. Immunostains
for S100, HMB-45, and Mart-1 were positive (See Fig. 2). A staging PET/
CT scan was negative for metastatic disease, and a pelvic MRI demon-
strated a 23 × 22 × 49 mm cervical lesion with concern for parametrial
extension. The patient underwent a type-III radical hysterectomy, bilater-
al salpingooophorectomy and pelvic lymphadenectomy with residualthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) High power (40×) H&E of primary ovarian melanoma. Positive melanoma immunostains; (B) S100, (C) Mart 1 and (D) HMB45.
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extending to the vaginawith extensive angiolymphatic invasion. Allmar-
gins were negative, as were 26 pelvic lymph nodes. Her post operative
course was complicated by a small bowel obstruction that resolved
with conservative management as well as a pelvic abscess which
required percutaneous drainage and antbiotics. A multidisciplinary
team recommended high-dose rate brachytherapy given the high-risk
features, which was completed 8 weeks after surgery, followed by sys-
temic therapy with ipilimumab. Unfortunately, she was hospitalized for
nausea and vomiting post-radiation, and imaging revealed metastaticFig. 2. (A) High power (40×) H&E of primary cervical melanoma. Positidisease with innumerable new liver and pulmonary metastases that
were not present on imaging 6 weeks earlier. She was lost to follow-up
anddied of disease 2months later (7months from initial diagnosis)with-
out receiving systemic therapy.
Comment
Gynecologicmelanomas are raremalignancies which can be difﬁcult
to diagnose and have a signiﬁcantly worse prognosis than cutaneous
melanoma, with 5 year survival rates of 11–25% compared to 81%ve melanoma immunostains; (B) S100, (C) Mart 1 and (D) HMB45.
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can have a variety of morphologic appearances, creating a wide differ-
ential diagnosis when not suspected clinically, and immunohistochem-
istry can be helpful in establishing the diagnosis (Carvajal et al., 2012).
Melanoma will frequently stain positive for S100, vimentin, Mart 1,
and HMB45. The combination of S100, which is more sensitive, and
HMB45, which is more speciﬁc, provides the most accurate diagnostic
criteria (Deshpande andMunshi, 2001). There are no known risk factors
for the development of gynecologic melanomas and universal staging
systems have not been shown to be predictive of clinical outcome. The
International Federation of Gynecologic Oncology staging system has
been shown to correlate with survival in cervical melanomas and the
Clark and Breslow systems have been proposed to have better prognos-
tic estimates for dermoid-associated ovarian melanoma (Sugiyama
et al., 2008; Carvajal et al., 2012). Prognostic factors are site speciﬁc
and not well-deﬁned for rare sites (Carvajal et al., 2012).
Surgical resection with wide margins remains the standard treat-
ment of melanoma, but can be challenging due to the multifocal nature
and lentiginous growth pattern of mucosal melanoma, as well as ana-
tomic constraints of the primary site (Carvajal et al., 2012). Many pa-
tients will recur distantly regardless of margin status, so morbidity of
initial resection must be balanced with overall prognosis. Because of
the high rate of local recurrence, post-operative radiotherapy has
become widely used in mucosal melanoma of the head and neck, with
improved local control rates in several series (Carvajal et al., 2012).
This beneﬁt has not been conﬁrmed in prospective clinical trials and
has not been demonstrated to impact overall survival, likely due to
the high rate of distant metastasis. Systemic therapy has not been spe-
ciﬁcally evaluated inmucosal or gynecologicmelanomas and has gener-
ally mirrored that of cutaneousmelanoma, including immune therapies
such as interleukin-2 and ipilimumab, aswell as targeted therapies, and
to a lesser extent, cytotoxic chemotherapy (Carvajal et al., 2012).
There have been 42 cases of primary ovarian melanoma reported in
the literature since 1901. The ovary does not contain melanocytes, and
most reported cases identiﬁed a coexistent teratoma as the purported
origin of melanocytes in the ovary. Proposed diagnostic criteria for pri-
marymelanomaof the ovary includes associationwith a teratoma in ad-
dition to exclusionof another primary site (Cronje andWoodruff, 1981).
The current case did not have teratoma elements identiﬁed on histopa-
thology, and thorough evaluation did not reveal another lesion at
presentation. It is possible that this was metastatic cutaneous disease
with regression of the primary lesion, however, the pattern of subse-
quent relapse in the paraaortic nodal chain is consistentwith an ovarian
primary. Presumably, this case arose from a small dermoid cyst or
monodermal teratoma that was then obliterated by bulky tumor
growth.
The prognosis following anovarianmelanomahas beendismal, even
with disease conﬁned to the ovary. Only one patient reported in the
literature has lived longer than 30 months and was without evidence
of disease at 5 years follow-up (Carlson andWheeler, 1993). The current
case of ovarian melanoma represents the longest survival reported, 69
months, despite metastatic disease early in her disease course. It is
also the second report of ovarian melanoma treated with immune-
therapy suggesting a role for biologic agents and multimodal therapy.
The remainder of reported patientswere treated primarilywith surgery,
less than half receiving adjuvant chemotherapy.
Eighty-one cases of primary cervical melanoma have been reported
in the literature. Cervicalmucosalmelanomausually presents as vaginal
bleeding or vaginal discharge. The basis of treatment is surgical excision
with wide margins, though there is no consensus on the optimal surgi-
cal approach to this disease; radical hysterectomy with pelviclymphadenectomy is frequently employed. Radiation has generally
been used for patients with advanced or unresectable disease, positive
margins or lymph nodes, parametrial involvement, or palliative treat-
ment of recurrence (Myriokefalitaki et al., 2013). Adjuvant radiation
has been successful in local control of head and neck mucosal melano-
mas, and may be applicable to other mucosal sites with high-risk fea-
tures. There are no cytotoxic chemotherapeutic regimens which have
proven effective in the treatment of mucosal melanoma. Recent success
in the treatment of cutaneousmelanomawith immunemodulating and
targeted therapies have not been speciﬁcally evaluated in mucosal mel-
anoma and have not been previously reported in cervical melanoma
(Mousavi et al., 2006). Prognosis, regardless of stage at diagnosis or
treatment approach, is poor. Five-year survival rates for stage I disease
range from 18.8–25%, 11.1–14% for stage II disease, and 0% for stage III
and stage IV disease (Sugiyama et al., 2008; Myriokefalitaki et al.,
2013). Rapid disease recurrence or progression can occur locally or dis-
tantly early after diagnosis, aswas seen in this case. Early visceralmetas-
tasis has universally been emphasized as an extremely poor prognostic
factor (Mousavi et al., 2006).
The strongest prognostic features of both disease sites are negative
resection margins and stage at diagnosis. Despite complete resection
of local disease, both cases had early distant metastasis. The fulminant
disease course of the cervical melanoma case compared to the ovarian
melanoma, may reﬂect the difference in biologic behavior of mucosal
versus cutaneous melanoma. The disparate outcomes of these two
cases highlight the limitations of traditional prognostic features, and fu-
ture study into molecular mechanisms of tumor biology may provide
more accurate clinical predictors.
In summary, we present two cases of rare gynecologic melanoma
treated with multimodal therapy by an interdisciplinary team. Ovarian
and cervical melanomas require a high index of suspicion from both
the treating gynecologist aswell as the pathologist. Immunohistochem-
istry can be instrumental in making the diagnosis. Prognosis is particu-
larly poor and optimal treatment is not known due to the rarity of these
malignancies, but generally mirrors that of cutaneous melanoma. The
basis of treatment is surgical excisionwith widemargins and should in-
clude a subspecialist familiar with radical surgery at the primary site of
the tumor. Multimodal therapy should be employed and referral to a
melanoma specialist familiar with immune and targeted-therapies is
recommended.
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